VCE-003 has been revealed to be a PPARγ partial agonist with no significant activity at CB1R and only moderate activity at CB2R. It has been explored successfully for its neuroinflammatory and neuroprotective properties in a murine model of multiple sclerosis [118]. This evidence concerns the gene CNR1 and multiple sclerosis.